Avaxia Biologic’s Barbara Fox Stays on the Run at BIO 2013
BIOWORLD By Marie Powers, Staff Writer | CHICAGO | April 2013
For Avaxia Biologics Inc., the decision to attend BIO 2013 was a no-brainer. The Lexington, Mass.-based company is in the middle of a Phase Ib study of lead compound AVX-470, an orally administered anti-TNF polyclonal antibody, in ulcerative colitis (UC). Results are expected in November, and if all goes well the company plans to report data in January 2014 at the J.P. Morgan Healthcare Conference in San Francisco.
Based on preclinical safety and efficacy findings, founder and CEO Barbara Fox said she is confident the company will move quickly into Phase IIa, and she’s in the hunt for a partner to move with her.